New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Seres Therapeutics, Inc. (MCRB) vs NewcelX Ltd. (NCEL)
- Seres Therapeutics, Inc. MCRB 1.24 −6.77%
- NewcelX Ltd. NCEL 2.54 −5.58%
Seres Therapeutics, Inc. and NewcelX Ltd. are both Biotechnology companies. Seres Therapeutics, Inc. and NewcelX Ltd. are of similar size ($14.5M and $13.6M). Across the 8 metrics below, Seres Therapeutics, Inc. leads on 5 and NewcelX Ltd. on 3.
Valuation
Profitability
| Metric | MCRB | NCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | — | 70.18% |
| Operating margin | (3,656.89%) | — | 0.00% |
| Net margin | (2,209.55%) | — | 0.00% |
| Free cash flow margin | — | — | 0.00% |
| Return on equity | (144.35%) | 165,532.11% | (51.58%) |
| Return on assets | (44.85%) | (596.85%) | (45.91%) |
| Return on invested capital | (1,267.77%) | — | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack